Triazine Sodium Channel Blockers for Neurological and Antimalarial Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders such as epilepsy, multiple sclerosis, glaucoma, cerebral traumas, and various neurodegenerative diseases lack effective sodium channel blockers and antifolates, and existing antimalarial agents are insufficient for treating malaria.
Innovation Solution
Development of triazine compounds with sodium channel blocking properties and antifolate activity, specifically 3,5-diamino-6-aryl-1,2,4-triazine derivatives, which can be administered as pharmaceutical compositions to treat these conditions, including cancers and malaria, by targeting sodium channels and dihydrofolate reductase enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for epilepsy, multiple sclerosis, glaucoma, cerebral traumas, and neurodegenerative diseases are used, then current therapeutic options are available, but effective sodium channel blockers and antifolates are lacking
Solution Approach 1:
The patent develops triazine compounds that simultaneously exhibit multiple therapeutic activities: sodium channel blocking, antifolate properties, and neuroprotective effects. This multi-functionality allows a single compound class to address multiple disorders including epilepsy, multiple sclerosis, glaucoma, cerebral traumas, and neurodegenerative diseases, thereby resolving the contradiction between having effective treatments for specific conditions and lacking versatility across different disorder types
2Reliability
If existing antimalarial agents are used, then malaria treatment is available, but sufficient efficacy is lacking
Solution Approach 1:
The patent modifies the chemical structure of triazine compounds by varying substituents at specific positions (R1-R6) to optimize antifolate activity and antimalarial efficacy. By systematically changing chemical parameters such as aromatic ring substitutions and side chain configurations, the invention enhances the efficacy of antimalarial treatment while maintaining manufacturability through established synthetic methodologies
3Adaptability or versatility
If triazine compounds are developed with multiple therapeutic activities, then treatment versatility is improved, but compound complexity increases
Solution Approach 1:
The patent divides the triazine compound structure into distinct functional segments: a core triazine ring system providing antifolate activity, aromatic substituents conferring sodium channel blocking properties, and specific side chains enabling neuroprotective effects. This segmentation allows each component to be optimized independently for its specific function while maintaining overall structural manageability and facilitating systematic development across multiple therapeutic applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The triazine compounds effectively treat a range of disorders by blocking sodium channels and inhibiting dihydrofolate reductase, offering potential as both neuroprotective agents and antimalarial therapies with minimal toxicity, as demonstrated by their ability to maintain ATP levels and inhibit specific enzyme activities.
Implementation Method 1
voltage-dependent sodium channel blockers for the treatment of disorders in mammals
Implementation Method 2
inhibiting dihydrofolate reductase
Data Source
AI summary
The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula (I): in which z is a single bond or an optionally substituted linking group, R1 is a halo-alkyl group; and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system; or a salt thereof.